Sagimet Biosciences (SGMT) Stock Forecast, Price Target & Predictions
SGMT Stock Forecast
Sagimet Biosciences stock forecast is as follows: an average price target of $6.00 (represents a 61.29% upside from SGMT’s last price of $3.72) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SGMT Price Target
The average price target for Sagimet Biosciences (SGMT) is $6.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 61.29% upside from SGMT's last price of $3.72.
SGMT Analyst Ratings
According to 5 Wall Street analysts, Sagimet Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for SGMT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Sagimet Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Andrea Tan | Goldman Sachs | $6.00 | $4.11 | 45.99% | 61.29% |
The latest Sagimet Biosciences stock forecast, released on Jun 28, 2024 by Andrea Tan from Goldman Sachs, set a price target of $6.00, which represents a 45.99% increase from the stock price at the time of the forecast ($4.11), and a 61.29% increase from SGMT last price ($3.72).
Sagimet Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $6.00 | $6.00 |
| Last Closing Price | $3.72 | $3.72 | $3.72 |
| Upside/Downside | -100.00% | 61.29% | 61.29% |
In the current month, the average price target of Sagimet Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sagimet Biosciences's last price of $3.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 28, 2024 | Goldman Sachs | Buy | Neutral | Downgrade |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 02, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Aug 08, 2023 | Piper Sandler | - | Overweight | Initialise |
| Aug 08, 2023 | Goldman Sachs | - | Buy | Initialise |
| Aug 08, 2023 | JMP Securities | - | Market Outperform | Initialise |
Sagimet Biosciences's last stock rating was published by JMP Securities on Aug 15, 2024. The company gave SGMT a "Outperform" rating, the same as its previous rate.
Sagimet Biosciences Financial Forecast
Sagimet Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Sagimet Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SGMT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Sagimet Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict SGMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Sagimet Biosciences's previous annual EBITDA (undefined) of $NaN.
Sagimet Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-36.17M | $-32.77M | $-28.94M | $-24.68M | $-19.04M | $-12.55M | $-10.58M |
| High Forecast | $-36.17M | $-32.77M | $-28.94M | $-24.68M | $-19.04M | $-11.48M | $-10.58M |
| Low Forecast | $-36.17M | $-32.77M | $-28.94M | $-24.68M | $-19.04M | $-13.89M | $-10.58M |
| Surprise % | - | - | - | - | - | - | - |
Sagimet Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SGMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Sagimet Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Sagimet Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SGMT last annual SG&A of $NaN (undefined).
Sagimet Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-1.13 | $-1.03 | $-0.91 | $-0.77 | $-0.60 | $-0.39 | $-0.33 |
| High Forecast | $-1.13 | $-1.03 | $-0.91 | $-0.77 | $-0.60 | $-0.36 | $-0.33 |
| Low Forecast | $-1.13 | $-1.03 | $-0.91 | $-0.77 | $-0.60 | $-0.44 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Sagimet Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SGMT previous annual EPS of $NaN (undefined).
SGMT Forecast FAQ
Is Sagimet Biosciences a good buy?
Yes, according to 5 Wall Street analysts, Sagimet Biosciences (SGMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of SGMT's total ratings.
What is SGMT's price target?
Sagimet Biosciences (SGMT) average price target is $6 with a range of $6 to $6, implying a 61.29% from its last price of $3.72. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sagimet Biosciences stock go up soon?
According to Wall Street analysts' prediction for SGMT stock, the company can go up by 61.29% (from the last price of $3.72 to the average price target of $6), up by 61.29% based on the highest stock price target, and up by 61.29% based on the lowest stock price target.
Can Sagimet Biosciences stock reach $6?
SGMT's average twelve months analyst stock price target of $6 does not support the claim that Sagimet Biosciences can reach $6 in the near future.
What are Sagimet Biosciences's analysts' financial forecasts?
Sagimet Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.18M (high $-41.111M, low $-43.515M), average SG&A $0 (high $0, low $0), and average EPS is $-1.322 (high $-1.288, low $-1.364). SGMT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-123M (high $-123M, low $-123M), average SG&A $0 (high $0, low $0), and average EPS is $-3.84 (high $-3.84, low $-3.84).